Core Insights - Biomerica, Inc. has announced the publication of a large multicenter clinical trial demonstrating the effectiveness of its inFoods® IBS diagnostic-guided therapy in managing Irritable Bowel Syndrome (IBS) symptoms [1][3][10] Study Overview - The clinical trial was randomized, multicenter, double-blind, and placebo-controlled, evaluating the inFoods® IBS test's ability to identify patient-specific dietary triggers and guide targeted food elimination [2][4] - The study involved 223 IBS patients across eight major U.S. academic medical centers, including renowned institutions like Mayo Clinic and Harvard Beth Israel Deaconess Medical Center [4] Key Findings - Patients following the inFoods® IBS-guided elimination diet experienced significantly greater symptom relief, with 59.6% achieving the FDA-defined target for abdominal pain reduction compared to 42.1% in the control group [9] - Particularly strong results were noted in difficult-to-treat IBS subtypes, with 67.1% of IBS-C patients and 66.0% of IBS-M patients responding positively to the treatment [9] Methodology and Innovation - The inFoods® IBS assay utilizes a proprietary discriminatory p-value method to identify foods causing abnormal IgG responses unique to IBS patients, allowing for a more focused dietary approach [7][10] - The study design addressed limitations of previous research by employing an IBS-specific food panel and robust statistical methodology, enhancing the reliability of the findings [6][10] Clinical Implications - The results support a shift towards precision medicine in gastrointestinal care, where individualized biological markers guide tailored treatment decisions rather than generalized approaches [12][11] - The inFoods® IBS protocol typically results in the elimination of only 2 to 4 foods per patient, making it a more practical and sustainable option compared to broader dietary strategies like the low-FODMAP diet [8][10] Recognition and Future Outlook - The inclusion of inFoods® IBS in Biotherapeutics Quarterly highlights the growing recognition of Biomerica's innovation among healthcare professionals [13] - The study's outcomes underscore the potential of diagnostic-guided dietary strategies to address unmet clinical needs, particularly for IBS-M patients, for whom no FDA-approved medications currently exist [11][12]

Core Insights - Teva Pharmaceuticals has received marketing authorizations from the European Commission for two denosumab biosimilar candidates, PONLIMSI and DEGEVMA, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) earlier this year [1][9]. Group 1: Product Approvals - The approvals of PONLIMSI and DEGEVMA represent a significant milestone in Teva's biosimilars portfolio, enhancing patient access to essential biologic therapies across Europe [2][9]. - Teva plans to launch both products in key European markets in the coming months, aligning with its Pivot to Growth strategy [2][9]. Group 2: Product Details - PONLIMSI is indicated for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as for bone loss associated with hormone ablation in men with prostate cancer [4][6]. - DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone [7][10]. Group 3: Mechanism of Action - Both PONLIMSI and DEGEVMA contain denosumab, a human monoclonal IgG2 antibody that targets the protein RANKL, crucial for the formation and survival of osteoclasts, thereby reducing bone resorption [5][8]. - PONLIMSI will be available as a 60mg/1mL solution for injection in a pre-filled syringe, while DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial [5][8]. Group 4: Company Commitment - Teva's leadership emphasizes the importance of these approvals in increasing patient access to biosimilar therapies for serious bone conditions, reflecting the company's commitment to improving healthcare options in Europe [3][9]. - The company aims to provide additional treatment options for healthcare systems, particularly in regions where access to biosimilars is limited [3].

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Core Points - Golar LNG Limited has successfully closed a new $1.2 billion asset-backed debt facility agreement for refinancing FLNG Gimi, replacing an existing facility with an outstanding amount of $627 million as of Q3 2025 [1][2] - The new debt facility has a 7-year tenor, a 16-year amortization profile, and incurs interest at SOFR plus a margin of 2.50% per annum [2] - Golar's 70% share of the net liquidity released from the refinancing amounts to approximately $400 million after repaying the existing Gimi debt facility and unwinding the existing interest-rate swap [2] - The CEO of Golar, Karl Fredrik Staubo, expressed satisfaction with the strong interest from leading international banks, indicating improved terms compared to the initial financing facility [3] - The new facility demonstrates the bankability of Golar's FLNG assets once operational, with a projected debt to EBITDA ratio of approximately 5.5x [3]

Core Insights - Xeriant Inc. is expanding its technology portfolio under the leadership of Brig. Gen. (Ret.) Blaine Holt, focusing on high-growth sectors such as artificial intelligence, quantum computing, and data science [1][6] - The company aims to create a collaborative technology ecosystem to accelerate the development of disruptive technologies [3] - Xeriant seeks to identify and advance innovations across aerospace and other sectors, positioning itself as a hub for transformative technologies [6] Company Strategy - Brig. Gen. Holt will target successful operating companies for acquisitions, licensing opportunities, or strategic partnerships to enhance Xeriant's technology offerings [1] - The company is assembling a diverse team of innovators to foster interdisciplinary teamwork and strong relationships within the technology landscape [3][4] - Xeriant's mission includes partnering with and acquiring strategic interests in visionary companies that align with its goals [8] Leadership Background - Brig. Gen. Holt has a distinguished career in both military and private sectors, including roles as the U.S. deputy military representative to NATO and CEO of AlchemAI, a software company focused on AI technology [4][5][7] - His experience in logistics, operations, and diplomacy is expected to provide valuable insights into identifying opportunities and synergies for Xeriant [4][7] Company Overview - Xeriant, Inc. is dedicated to the discovery, development, and commercialization of transformative technologies, including advanced materials marketed under the DUREVER™ brand [8] - The company's advanced materials include NEXBOARD™, an eco-friendly composite construction panel designed to replace traditional building materials [8]

Core Insights - Skyworks Solutions, Inc. will participate in a fireside chat at the UBS Global Technology and AI Conference on December 2, 2025, at 2:15 p.m. MST [1] - The event will be available for live webcast and archived for replay for one week on Skyworks' website [2] Company Overview - Skyworks Solutions, Inc. is a leading developer and manufacturer of high-performance analog and mixed-signal semiconductors for various applications, including aerospace, automotive, broadband, cellular infrastructure, connected home, defense, entertainment, gaming, industrial, medical, smartphones, tablets, and wearables [3] - The company operates globally with facilities in Asia, Europe, and North America and is a member of the S&P 500 market index [4]

Atlanta, GA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- ScanTech AI Systems Inc. (the "Company" or "ScanTech AI") (Nasdaq: STAI), a developer of advanced AI-powered security screening and imaging systems, today announced a strategic partnership with unival group, a global leader in security systems integration headquartered in Bonn, Germany. The partnership combines ScanTech AI’s SENTINEL® CT security platform—featuring multi-angle computed tomography, AI-based automatic threat detection, and real-time analytics, wi ...

Core Viewpoint - Nuvectis Pharma, Inc. is hosting a virtual Key Opinion Leader Meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, particularly its combination with osimertinib in non-small cell lung cancer [1][2]. Company Overview - Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative precision medicines for serious unmet medical needs in oncology [1][8]. - The lead drug candidate, NXP900, is an oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), including SRC and YES1, designed to inhibit both catalytic and scaffolding functions of the SRC pathway [6][8]. NXP900 Development - NXP900 has completed a Phase 1a dose escalation study in patients with advanced solid tumors and is currently undergoing a Phase 1b single agent dose expansion study [7][8]. - A drug-drug interaction study has been completed, supporting the initiation of enrollment in the Phase 1b dose expansion combination arm, expected to begin by the end of 2025 [7]. Key Opinion Leaders - The meeting will feature Dr. Alexander Spira, Chief Scientific Officer of NEXT Oncology, and Dr. Asier Uncita-Broceta, Professor of Chemistry at the University of Edinburgh, who will discuss NXP900's development program and clinical data [2][4][5].

First-of-its-Kind Investment Provides Direct Exposure to Telegram's $3 Billion Projected Annual Revenue paying ~9% APY with Convertible discount of 20% in a Telegram Change of Control Scenario, in addition, ATON will use the 9% APY to accumulate more TON Coin for its Digital Asset TreasuryTORTOLA, BVI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (NASDAQ: ATON), a leading digital asset technology company focused on the Telegram and TON ecosystem, today announced its strategic interest in acquiri ...

Core Viewpoint - Compass Therapeutics, Inc. is actively engaging with investors through participation in key healthcare conferences in December 2025, highlighting its focus on oncology and proprietary antibody-based therapeutics [1][2]. Group 1: Upcoming Investor Events - Compass Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:00 AM ET in New York, NY [2]. - The company will also attend the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:00 AM ET in Coral Gables, FL [2]. - Presentations from these events will be archived for 90 days on Compass' Events page, allowing for virtual/replay availability [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology [4]. - The company’s research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - The therapeutic strategies include targeting angiogenesis, inducing immune responses, and overcoming immunosuppressive mechanisms utilized by tumors [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].